Amgen delivered strong quarterly results, yet its stock has been falling. Explore the key reasons, including clinical setbacks, rising competition, and valuation concerns.
Danaher is acquiring Masimo in a $9.9 billion all-cash deal. Here’s what the acquisition means for DHR stock, Masimo’s Apple litigation, and long-term investors.
Get ready for higher prices. The bull market in solar energy is back on.
Over the past four months, I’ve repeatedly made the case for owning solar energy stocks.
Alzheimer's drug sales are gaining momentum as Leqembi and Kisunla expand globally and new P-Tau blood tests transform diagnosis. Here's what biotech investors need to know.